| Literature DB >> 23725297 |
Abstract
BACKGROUND: Public domain databases nowadays provide multiple layers of genome-wide data e.g., promoter methylation, mRNA expression, and miRNA expression and should enable integrative modeling of the mechanisms of regulation of gene expression. However, researches along this line were not frequently executed.Entities:
Year: 2013 PMID: 23725297 PMCID: PMC3693885 DOI: 10.1186/1756-0381-6-11
Source DB: PubMed Journal: BioData Min ISSN: 1756-0381 Impact factor: 2.522
Figure 1Schematic illustration of the relationship between miRNA-mediated gene regulation and miRNA-targeted-specific promoter methylation. Arrows/segments indicate up/downregulation of miRNA target genes (a) and miRNA-targeted-specific promoter methylation (b). Black (red) numbers next to inequality signs are the averaged number of miRNAs whose target genes are significantly up/downregulated (whose target genes promoters are hyper/hypomethylated). TCTX refers to the temporal cortex, FCTX to the frontal cortes, CRBLM to the cerebellum, and PONS to the pons. For example, there are 280 (183) miRNAs whose target gene promoters are significantly hyper(hypo)methylated in FCFX compared to TCTX. Similarly, there are 889 (173) miRNAs whose target genes are significantly up(down)regulated in FCFX compared to TCTX. Since 280 is larger than 183, gene promoters in FCFX are considered to be more hypermethylated than those in TCTX based on the miRNA-centric-view, thus the red arrow directs the reader from TCTX to FCTX. Likewise, because 889 is larger than 173, genes in FCFX are considered to be upregulated when compared to TCTX, thus the black arrow directs the reader from TCTX to FCTX. The numbers in the rectangle indicate Spearman correlation coefficients between miRNA-mediated gene regulation and miRNA-targeted-specific promoter methylation, . Standard deviations of Spearman correlation coefficients, are shown in parentheses.
miRNAs that significantly regulate target genes
| hsa-miR-20a-5p | |||||
| hsa-miR-135a-5p | hsa-miR-23a-3p | | |||
| hsa-miR-202-3p * | | ||||
| hsa-miR-561-3p | hsa-miR-10a-5p | | |||
| hsa-miR-369-3p | hsa-miR-568 | | | ||
| hsa-miR-487a * | hsa-miR-618 | hsa-miR-223–3p | FCFX vs PONS | ||
| hsa-miR-514a-3p | hsa-miR-126-3p | hsa-miR-365a-3p | |||
| hsa-miR-553 | | hsa-miR-134 | hsa-miR-378a-5p | ||
| hsa-miR-554 | | hsa-miR-154-3p | | hsa-miR-595 | |
| hsa-miR-655 | | | | ||
| hsa-miR-421 | | FCTX vs TCTX | |||
| | | hsa-miR-377-3p | has-miR-373-3p | ||
| | | hsa-miR-383 | | ||
| | | hsa-miR-431-5p | | ||
| | | hsa-miR-571 | hsa-miR-329 | | |
| | | hsa-miR-549 | PONS VS TCTX | ||
| | | | hsa-miR-487a * | ||
| | | | hsa-miR-202-3p * | ||
| | | | hsa-miR-410 | ||
| | | | hsa-miR-495 | hsa-miR-487b | hsa-miR-581 |
| | | | hsa-miR-504 | ||
| | | | hsa-miR-505-3p | | |
| | | | hsa-miR-563 | | |
| | | | hsa-miR-578 | | |
| | | | | | |
miRNAs predicted to regulate target genes based on six pairwise comparisons among four brain regions: the frontal cortex (FCTX), temporal cortex (TCTX), pons (PONS), and cerebellum (CRBLM). The labels “Reciprocal” and “nonreciprocal” indicate whether the observed relationship between miRNA expression and target gene mRNA was either reciprocal or nonreciprocal. Asterisked miRNAs appear more than once. Bold faced miRNAs were previously reported to be related to brain development/diseases [37-39]. See subsection “The selection of miRNAs that significantly regulate target genes based on multiple regression model” in Supplementary Document (see Additional file 1) for the detailed criterion of miRNAs selection.
miRNA target genes KEGG pathway enrichment
| | | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | ||||||||||||
| | | ||||||||||||
| 1 | ○ | ○ | ○ | ○ | | | | ○ | | | ○ | | |
| 2 | Glioma ∗ | ○ | ○ | ○ | ○ | ○ | | | ○ | | | | |
| 3 | ○ | ○ | ○ | ○ | | | | | | ○ | | | |
| 4 | Axon guidance ∗ | ○ | ○ | ○ | ○ | | | | | | | | |
| 5 | Phosphatidylinositol signaling system | ○ | ○ | | ○ | | | | | | | | |
| 6 | ○ | ○ | ○ | | | | | | | | | | |
| 7 | Adipocytokine signaling pathway | ○ | ○ | | ○ | | ○ | | | | | | |
| 8 | Pancreatic cancer | ○ | ○ | | ○ | | | | ○ | | | | |
| 9 | ○ | ○ | ○ | ○ | | | | | | | ○ | | |
| 10 | ○ | ○ | ○ | ○ | | | | | | | ○ | | |
| 11 | Insulin signaling pathway | ○ | ○ | ○ | ○ | | | | | | | | |
| 12 | Neurotrophin signaling pathway ∗ | ○ | ○ | ○ | ○ | | | | | | | | |
| 13 | Colorectal cancer | ○ | ○ | ○ | ○ | | | | | | | | |
| 14 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ○ | ○ | ○ | ○ | | | | | | ○ | | |
| 15 | ○ | ○ | ○ | ○ | | ○ | | | | ○ | | | |
| 16 | Non-small cell lung cancer | ○ | ○ | | | | | | | | | | |
| 17 | ○ | ○ | ○ | ○ | | | | | | | ○ | | |
| 18 | ○ | ○ | ○ | ○ | | | | | | | | | |
| 19 | Pathways in cancer | ○ | ○ | ○ | ○ | | | | ○ | | | ○ | |
| 20 | Glycosaminoglycan biosynthesis - heparan sulfate | ○ | ○ | ○ | ○ | | | | ○ | ○ | | | |
| 21 | Type II diabetes mellitus | ○ | ○ | | | | | | | | | | |
| 22 | Melanoma | ○ | ○ | | ○ | | | | ○ | | | | |
| 23 | Renal cell carcinoma | ○ | ○ | ○ | ○ | | | | | | | | |
| 24 | Inositol phosphate metabolism | ○ | ○ | | | | | | | | | | |
| 25 | Chronic myeloid leukemia | ○ | ○ | ○ | ○ | | | | ○ | | | | |
| 26 | T cell receptor signaling pathway | ○ | ○ | | | | | | | | | | |
| 27 | Small cell lung cancer | ○ | ○ | ○ | | | | | | | | | |
| 28 | Fc gamma R-mediated phagocytosis | ○ | ○ | | ○ | | | | | | | | |
| 29 | Prostate cancer | ○ | ○ | ○ | | | | | | | | | |
| 30 | Salivary secretion | ○ | ○ | | | | | | | | | | |
| 31 | Osteoclast differentiation | ○ | ○ | | | | | | | | | | |
| 32 | ○ | ○ | ○ | ○ | | | | | | | | | |
| 33 | Endocrine and other factor-regulated calcium reabsorption | ○ | ○ | | | | | | | | | | |
| 34 | | | ○ | ○ | | ○ | | | | | | | |
| 35 | Circadian rhythm - mammal | | | ○ | ○ | | | | ○ | | ○ | | |
| 36 | Glycosaminoglycan biosynthesis - chondroitin sulfate | | | ○ | ○ | | | | | ○ | | | |
| 37 | | | ○ | ○ | | | | | | | | | |
| 38 | | | | ○ | | | | ○ | | | | | |
| 39 | | | | ○ | | | | | | | ○ | | |
| 40 | | | ○ | | | | | | ○ | | | | |
| 41 | | | | ○ | | | | | | ○ | | | |
| 42 | Hypertrophic cardiomyopathy (HCM) | | | | ○ | | | | | | ○ | | |
| 43 | Cell adhesion molecules (CAMs) | | | | | | ○ | ○ | | | | | |
| 44 | Dilated cardiomyopathy | | | | ○ | | | | | | ○ | | |
| 45 | Fatty acid biosynthesis | ○ | | | | | | | | | | | |
| 46 | | | ○ | | | | | | | | | | |
| 47 | Ubiquitin mediated proteolysis | | | ○ | | | | | | | | | |
| 48 | Thyroid cancer | | | ○ | | | | | | | | | |
| 49 | Notch signaling pathway | | | ○ | | | | | | | | | |
| 50 | Mismatch repair | | | ○ | | | | | | | | | |
| 51 | Acute myeloid leukemia | | | ○ | | | | | | | | | |
| 52 | Glycosphingolipid biosynthesis - lacto and neolacto series | | | ○ | | | | | | | | | |
| 53 | Glycosaminoglycan biosynthesis - keratan sulfate | | | | ○ | | | | | | | | |
| 54 | Biotin metabolism | | | | ○ | | | | | | | | |
| 55 | Gap junction | | | | ○ | | | | | | | | |
| 56 | Gastric acid secretion | | | | ○ | | | | | | | | |
| 57 | Taurine and hypotaurine metabolism | | | | ○ | | | | | | | | |
| 58 | Aldosterone-regulated sodium reabsorption | | | | ○ | | | | | | | | |
| 59 | GnRH signaling pathway | | | | ○ | | | | | | | | |
| 60 | Metabolism of xenobiotics by cytochrome P450 | | | | | | ○ | | | | | | |
| 61 | Mucin type O-Glycan biosynthesis | | | | | | | | ○ | | | | |
| 62 | Biosynthesis of unsaturated fatty acids | | | | | | | | | ○ | | | |
| 63 | Viral myocarditis | | | | | | | | | | ○ | | |
| 64 | Cytokine-cytokine receptor interaction | | | | | | | | | | | ○ | |
| 65 | Hematopoietic cell lineage | | | | | | | | | | | ○ | |
| 66 | Valine, leucine and isoleucine biosynthesis | ○ | |||||||||||
KEGG pathways marked with ○ are enriched by target genes of miRNAs selected in Table 1. “R” and “N” indicate whether the relationship between miRNA expression and target gene mRNA is reciprocal (nonreciprocal). Pathways asterisked and bold faced are directly related to brain and neurons, respectively, and discussed in detail in the Supplementary Document (see Additional file 1).